Stoke Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
STOK$27.71+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $127,983 | $191,442 |
| Marketable securities - short term | 88,916 | 9,952 |
| Prepaid expenses | 11,117 | 11,320 |
| Other current assets | 3,965 | 2,561 |
| Restricted cash - short term | 75 | — |
| Interest receivable | 700 | 64 |
| Total current assets | $232,756 | $215,339 |
| Restricted cash - long term | 721 | 569 |
| Operating lease right-of-use assets | 4,345 | 6,611 |
| Marketable securities - long term | 29,824 | — |
| Property and equipment, net | 3,909 | 5,823 |
| Total assets | $271,555 | $228,342 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,498 | $1,695 |
| Accrued and other current liabilities | 18,567 | 13,815 |
| Deferred revenue - current portion | 18,991 | 15,309 |
| Total current liabilities | $40,056 | $30,819 |
| Deferred revenue - net of current portion | — | 33,074 |
| Other long term liabilities | 2,478 | 4,884 |
| Total long term liabilities | $2,478 | $37,958 |
| Total liabilities | $42,534 | $68,777 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 54,032,826 and 45,918,233 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 5 | 5 |
| Additional paid-in capital | 719,997 | 561,433 |
| Accumulated other comprehensive loss | (151) | (24) |
| Accumulated deficit | (490,830) | (401,849) |
| Total stockholders’ equity | $229,021 | $159,565 |
| Total liabilities and stockholders’ equity | $271,555 | $228,342 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.